Relief Therapeutics - eine COVID-19 Hoffnung? (Seite 488)
eröffnet am 11.03.20 17:46:44 von
neuester Beitrag 27.04.24 16:05:40 von
neuester Beitrag 27.04.24 16:05:40 von
Beiträge: 14.080
ID: 1.321.697
ID: 1.321.697
Aufrufe heute: 32
Gesamt: 2.518.135
Gesamt: 2.518.135
Aktive User: 0
ISIN: CH1251125998 · WKN: A3EFB5 · Symbol: RLF
1,3000
CHF
+4,00 %
+0,0500 CHF
Letzter Kurs 26.04.24 SIX Swiss (CHF)
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 | |
| 4,7450 | +35,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
So ein Schwachsinn.
YF
rk3 hours ago
Todays Woodland Report fron 40 mins,ago:
Shares of Big Rock Partners Acquisition (BRPA) surged on high volatility and has received a couple trade halts in early market trading.
Currently, BRPA is a special acquisition company or SPAC that announced a couple months ago its intended merger with molecule pharmaceutical company NeuroRx, the company excels at rapid development of already-known molecules to deliver lifesaving solutions in record time at minimum cost. The proposed business combination between the two companies, if approved by the stockholders of BRPA and NeuroRx, is currently expected to close in Q2 2021.
One molecule that the company is developing is Zyesami (or Aviptadil/RLF-100), created, developed and patented by Relief Therapeutics (RLFTF) for the treatment of COVID-19 related lung injury and acute respiratory failure.
To sum it all up, Zyesami’s clinical trials showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
rk3 hours ago
Todays Woodland Report fron 40 mins,ago:
Shares of Big Rock Partners Acquisition (BRPA) surged on high volatility and has received a couple trade halts in early market trading.
Currently, BRPA is a special acquisition company or SPAC that announced a couple months ago its intended merger with molecule pharmaceutical company NeuroRx, the company excels at rapid development of already-known molecules to deliver lifesaving solutions in record time at minimum cost. The proposed business combination between the two companies, if approved by the stockholders of BRPA and NeuroRx, is currently expected to close in Q2 2021.
One molecule that the company is developing is Zyesami (or Aviptadil/RLF-100), created, developed and patented by Relief Therapeutics (RLFTF) for the treatment of COVID-19 related lung injury and acute respiratory failure.
To sum it all up, Zyesami’s clinical trials showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
Jetzt ist es raus: "Unsere Formulierung von Zyesami ist durch kein Patebt abgedeckt und könnte in Zukunft einem Wettbewerb der Herkunft ausgesetzt sein" (aus dem SECfiling wozu jedoch kein Link angegeben wurde)
Das Aviptadil-Patent decke Zyesami nicht ab.
Sorry, dass ich das posten muss, jetzt wird es wohl einen Patentstreit geben
Geert 2 minutes ago yahooforum
What does it this means ; comes from SEC filing :
Our formulation of ZYESAMI is not covered by an existing patent and may be subject to future generic competition.
ZYESAMI is not currently covered by any US or international patent. US Patent 8178489B2 and foreign counterparts does not apply to ZYESAMI because it covers only formulations of aviptadil that are formulated in
68
Table of Contents
a buffer. Laboratory evidence suggests that Vasoactive Intestinal Peptide (aviptadil) aggregates and may be inactivated by known buffers. NeuroRx is engaged in a discovery process to extend the stability of ZYESAMI and has made certain discoveries that may lead to future patent filings and which may or may not lead to allowed patent claims. In the event that no patent protection is granted covering the formulation of ZYESAMI, if the drug is approved by FDA, it is anticipated to receive at least five years of data exclusivity from the FDA under what is commonly known as “paragraph 4” protections. Should no patents be granted by the end of this data exclusivity period, competitors may be able to market generic versions of ZYESAMI.
Less
Das Aviptadil-Patent decke Zyesami nicht ab.
Sorry, dass ich das posten muss, jetzt wird es wohl einen Patentstreit geben
Geert 2 minutes ago yahooforum
What does it this means ; comes from SEC filing :
Our formulation of ZYESAMI is not covered by an existing patent and may be subject to future generic competition.
ZYESAMI is not currently covered by any US or international patent. US Patent 8178489B2 and foreign counterparts does not apply to ZYESAMI because it covers only formulations of aviptadil that are formulated in
68
Table of Contents
a buffer. Laboratory evidence suggests that Vasoactive Intestinal Peptide (aviptadil) aggregates and may be inactivated by known buffers. NeuroRx is engaged in a discovery process to extend the stability of ZYESAMI and has made certain discoveries that may lead to future patent filings and which may or may not lead to allowed patent claims. In the event that no patent protection is granted covering the formulation of ZYESAMI, if the drug is approved by FDA, it is anticipated to receive at least five years of data exclusivity from the FDA under what is commonly known as “paragraph 4” protections. Should no patents be granted by the end of this data exclusivity period, competitors may be able to market generic versions of ZYESAMI.
Less
Ist die Rakete von BRPP das Signal zum Nachlegen von RLF-Aktien?
Wenn BRPP so schnell hochgeht, wie viel höher müsste RLF dann gehen?
Wenn BRPP so schnell hochgeht, wie viel höher müsste RLF dann gehen?
Trading Spotlight
Antwort auf Beitrag Nr.: 68.260.357 von Rolf1K am 20.05.21 21:09:53OTC +7.7% für Relief
Big Rock aktuell 122 %plus, gibt es dazu eine logische Erklärung? Sie haben doch nur Neurorx. Wissen vielleicht die Insider, dass Relief/Neurorx die EUA erhält? Das wäre eine plausible Erklärung.
Und dann können wir auf ein Feuerwerk bei RLF hoffen/erwarten
Und dann können wir auf ein Feuerwerk bei RLF hoffen/erwarten
Antwort auf Beitrag Nr.: 68.257.009 von TomR7 am 20.05.21 16:38:16https://upload.wikimedia.org/wikipedia/commons/thumb/a/a7/Va…
Antwort auf Beitrag Nr.: 68.258.407 von beidlwatschen am 20.05.21 18:18:41
https://www.sec.gov/Archives/edgar/data/1719406/000119312521…
hier der Link dazu
Zitat von beidlwatschen: Big Rock 🤪
https://www.sec.gov/Archives/edgar/data/1719406/000119312521…
hier der Link dazu
Big Rock 🤪
Durchsuchen
Relief Therapeutics - eine COVID-19 Hoffnung?
